Product Description
"
Alectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).
It was approved by the US Food and Drug Administration (FDA) in December 2015 to treat patients with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori)
It got a conditional approval by the European Medicines Agency in February 2017 for the same indication. This means that additional studies are awaited to confirm a positive benefit-risk-ratio.
The material 4-Ethyl-3-iodo-alpha,alpha-dimethylbenzeneacetic acid
(CAS Registry Number 1256584-73-2 ) is the key intermediate used for Alectinib.
"
![132112-67-5, Bicyclo[2.2.1]heptane-2,6-dicarbonitrile](https://www.pudeepharm.com/wp-content/uploads/2024/05/675.jpg)
![189253-72-3, (2-{2-[(3-aminopropyl)(methyl)amino]ethoxy}ethyl)dimethylamine](https://www.pudeepharm.com/wp-content/uploads/2024/05/723.jpg)
![835914-81-3, 4-[[4-[[6-[[1-Amino-8-hydroxy-7-[(4-nitro-2-sulfophenyl)azo]-4,6-disulfo-2-naphthalenyl]azo]-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]-2-chloro-6-sulfophenyl]azo]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid, lithium sodium salt](https://www.pudeepharm.com/wp-content/uploads/2024/05/813.jpg)
